Education and Training

Radiation Therapy Residency

Medical Students

Medical Physics Residency

Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy

This is a phase 2/3 open-label study to evaluate the long-term safety, tolerability, and efficacy of sibeprenlimab administered subcutaneously (SC) in subjects with IgAN.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • drug: Sibeprenlimab 400 mg s.c. Q4weeks

Eligibility


Inclusion Criteria:

   - Subjects who completed Trial 417-201-00007 or VIS649-201 without safety concerns and
   who, in the opinion of the investigator, could potentially benefit from treatment with
   sibeprenlimab.

   - eGFR ≥ 20 mL/min/1.73 m2, calculated using the Chronic Kidney Disease Epidemiology
   Collaboration (CKD-EPI) formula.

Exclusion Criteria:

   - Subjects who have not completed participation in trials 417-201-00007 or VIS649-201.

   - Subjects who, following enrollment in trials 417-201-00007 or VIS649-201 developed a
   condition or characteristic that would have excluded them from participation in these
   trials.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Shiktj Dave
650-723-2240
I'm interested